These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 22564985

  • 1. Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry.
    Neukirchen J, Fox F, Kündgen A, Nachtkamp K, Strupp C, Haas R, Germing U, Gattermann N.
    Leuk Res; 2012 Aug; 36(8):1067-70. PubMed ID: 22564985
    [Abstract] [Full Text] [Related]

  • 2. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
    Delforge M, Selleslag D, Triffet A, Mineur P, Bries G, Graux C, Trullemans F, MacDonald K, Abraham I, Pluymers W, Ravoet C.
    Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
    [Abstract] [Full Text] [Related]

  • 3. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
    Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, Larbaa D, Dreyfus F, Beyne-Rauzy O, Chaury MP, Roy L, Cheze S, Morel P, Fenaux P, GFM (Groupe Francophone des Myélodysplasies).
    Leuk Res; 2010 Jul; 34(7):864-70. PubMed ID: 20129667
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes.
    Delforge M, Selleslag D, Beguin Y, Triffet A, Mineur P, Theunissen K, Graux C, Trullemans F, Boulet D, Van Eygen K, Noens L, Van Steenweghen S, Lemmens J, Pierre P, D'hondt R, Ferrant A, Deeren D, Van De Velde A, Wynendaele W, André M, De Bock R, Efira A, Breems D, Deweweire A, Geldhof K, Pluymers W, Harrington A, MacDonald K, Abraham I, Ravoet C.
    Leuk Res; 2014 May; 38(5):557-63. PubMed ID: 24661630
    [Abstract] [Full Text] [Related]

  • 6. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
    Leitch HA.
    Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
    [Abstract] [Full Text] [Related]

  • 7. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
    Gattermann N.
    Leuk Res; 2007 Dec; 31 Suppl 3():S10-5. PubMed ID: 18037413
    [Abstract] [Full Text] [Related]

  • 8. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
    Raptis A, Duh MS, Wang ST, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J.
    Transfusion; 2010 Jan; 50(1):190-9. PubMed ID: 19719471
    [Abstract] [Full Text] [Related]

  • 9. The deleterious effects of iron overload in patients with myelodysplastic syndromes.
    Dreyfus F.
    Blood Rev; 2008 Dec; 22 Suppl 2():S29-34. PubMed ID: 19059054
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
    Leitch HA, Parmar A, Wells RA, Chodirker L, Zhu N, Nevill TJ, Yee KWL, Leber B, Keating MM, Sabloff M, St Hilaire E, Kumar R, Delage R, Geddes M, Storring JM, Kew A, Shamy A, Elemary M, Lenis M, Mamedov A, Ivo J, Francis J, Zhang L, Buckstein R.
    Br J Haematol; 2017 Oct; 179(1):83-97. PubMed ID: 28677895
    [Abstract] [Full Text] [Related]

  • 12. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions.
    Chacko J, Pennell DJ, Tanner MA, Hamblin TJ, Wonke B, Levy T, Thomas PW, Killick SB.
    Br J Haematol; 2007 Sep; 138(5):587-93. PubMed ID: 17610536
    [Abstract] [Full Text] [Related]

  • 13. Iron chelation therapy in myelodysplastic syndrome - Cui bono?
    Tefferi A, Stone RM.
    Leukemia; 2009 Aug; 23(8):1373. PubMed ID: 19672273
    [No Abstract] [Full Text] [Related]

  • 14. Controversies surrounding iron chelation therapy for MDS.
    Leitch HA.
    Blood Rev; 2011 Jan; 25(1):17-31. PubMed ID: 21030120
    [Abstract] [Full Text] [Related]

  • 15. Iron chelation therapy in MDS: what have we learnt recently?
    Schmid M.
    Blood Rev; 2009 Dec; 23 Suppl 1():S21-5. PubMed ID: 20116636
    [Abstract] [Full Text] [Related]

  • 16. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
    Maurillo L, Breccia M, Buccisano F, Voso MT, Niscola P, Trapè G, Tatarelli C, D'Addosio A, Latagliata R, Fenu S, Piccioni AL, Fragasso A, Aloe Spiriti MA, Refrigeri M, Criscuolo M, Musto P, Venditti A.
    Eur J Haematol; 2015 Jul; 95(1):52-6. PubMed ID: 25764148
    [Abstract] [Full Text] [Related]

  • 17. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.
    Jabbour E, Kantarjian HM, Koller C, Taher A.
    Cancer; 2008 Mar 01; 112(5):1089-95. PubMed ID: 18186499
    [Abstract] [Full Text] [Related]

  • 18. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications.
    Remacha ÁF, Arrizabalaga B, Villegas A, Durán MS, Hermosín L, de Paz R, Garcia M, Diez Campelo M, Sanz G, IRON-2 Study Group.
    Ann Hematol; 2015 May 01; 94(5):779-87. PubMed ID: 25516455
    [Abstract] [Full Text] [Related]

  • 19. Impact of iron overload in myelodysplastic syndromes.
    Fenaux P, Rose C.
    Blood Rev; 2009 Dec 01; 23 Suppl 1():S15-9. PubMed ID: 20116635
    [Abstract] [Full Text] [Related]

  • 20. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.
    Leitch HA.
    Drugs; 2011 Jan 22; 71(2):155-77. PubMed ID: 21275444
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.